Key Areas of Cancer Research To Be Presented by Thought Leaders at Atlantic Health System’s 2021 Annual Review in Oncology Virtual Symposium

Atlantic Health System Cancer Care will continue its tradition of world-class medical education by hosting its 2021 Annual Review in Oncology Virtual Symposium. The symposium, held via Microsoft Teams with free registration, will take place Saturday, June 26, 2021, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the nation’s leading cancer centers will summarize the latest advances in six areas of oncology, as presented at the just-completed ASCO conference—the world’s premiere meeting for cancer care professionals and researchers.

New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer

Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.

Moffitt Cancer Center Experts to Present New Clinical Research Data

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentations, five education sessions, two cancer-based panels and two clinical science symposia. The virtual meeting is June 4-8.

Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting

Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…

Combination therapy achieves high rates of response for patients with acute lymphoblastic leukemia

A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Extensive, Wide-Ranging New Cancer Research Data at the 2021 ASCO Annual Meeting

Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8.